How should we manage patients with non-alcoholic fatty liver disease in 2007?

by Chan, H.L.-Y., De Silva, H.J., Leung, N.W.-Y., Lim, S.-G., Farrell, G.C.
Published 2016

Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy

by Lui, Y.Y.N., Tsoi, K.K.F., Wong, V.W.S., Kao, J.H., Hou, J.L., Teo, E.K., Mohamed, R., Piratvisuth, T., Han, K.H., Mihm, U., Wong, G.L.H., Chan, H.L.Y.
Published 2010

Prevention of hepatocellular carcinoma in the Asia-Pacific region: Consensus statements

by Farrell, G.C., Chan, H.L.Y., Yuen, M.F., Amarapurkar, D.N., Chutaputti, A., Fan, J.G., Hou, J.L., Han, K.H., Kao, J.H., Lim, S.G., Mohamed, R., Sollano, J., Ueno, Y., Prevent, Asai-Pacific Working Party
Published 2010

Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B

by Wang Y., Thongsawat S., Gane E.J., Liaw Y.-F., Jia J., Hou J., Chan H.L.Y., Papatheodoridis G., Wan M., Niu J., Bao W., Trylesinski A., Naoumov N.V.
Published 2014

Chronic hepatitis B: Whom to treat and for how long? Propositions, challenges, and future directions

by Ahn, S.H., Chan, H.L.Y., Chen, P.-J., Cheng, J., Goenka, M.K., Hou, J., Lim, S.G., Omata, M., Piratvisuth, T., Xie, Q., Yim, H.J., Yuen, M.-F.
Published 2011

Treatment of hepatitis B e antigen-positive chronic hepatitis with telbivudine or adefovir: A randomized trial

by Chan, H.L.Y., Heathcote, E.J., Marcellin, P., Lai, C.-L., Cho, M., Moon, Y.M., Chao, Y.-C., Myers, R.P., Minuk, G.Y., Jeffers, L., Sievert, W., Bzowej, N., Harb, G., Kaiser, R., Qiao, X.-J., Brown, N.A., Crawford, D., Lim, S.-G., Chutaputti, A., Poynard, T.
Published 2016